Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2010 1
2011 2
2012 2
2013 3
2014 3
2015 2
2016 3
2017 5
2019 1
2020 4
2021 4
2022 2
2023 8
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for shen hong qin
Your search for Shenghong Qin retrieved no results
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Chang J, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Wang J, Li P, Qin M, Lu D, Yang J. Zhou C, et al. Among authors: shen h. Lancet Oncol. 2022 Feb;23(2):220-233. doi: 10.1016/S1470-2045(21)00650-1. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038432 Clinical Trial.
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.
Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, Yu Y, Yao W, Sun S, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Hu C, Liu J, Liu Y, Wang M, Li X, Sun P, Shu Y, Zhou J, Li J, Gu K, Wang C, Zhao H, Zhang Y, Liu C, Wang J, Chen R, Qin M, Wang H, Yang J. Zhou C, et al. Among authors: shen h. Nat Cancer. 2023 Jun;4(6):860-871. doi: 10.1038/s43018-023-00578-z. Epub 2023 Jun 15. Nat Cancer. 2023. PMID: 37322367 Clinical Trial.
A network pharmacology approach and experimental validation to investigate the anticancer mechanism of Qi-Qin-Hu-Chang formula against colitis-associated colorectal cancer through induction of apoptosis via JNK/p38 MAPK signaling pathway.
Wu Y, Fang Y, Li Y, Au R, Cheng C, Li W, Xu F, Cui Y, Zhu L, Shen H. Wu Y, et al. Among authors: shen h. J Ethnopharmacol. 2024 Jan 30;319(Pt 3):117323. doi: 10.1016/j.jep.2023.117323. Epub 2023 Oct 16. J Ethnopharmacol. 2024. PMID: 37852337 Free article.
ETHNOPHARMACOLOGICAL RELEVANCE: The Qi-Qin-Hu-Chang Formula (QQHCF) is a traditional Chinese medicine prescription that is clinically used at the Affiliated Hospital of Nanjing University of Chinese Medicine for the treatment of colitis-associated colorectal cancer (CAC). …
ETHNOPHARMACOLOGICAL RELEVANCE: The Qi-Qin-Hu-Chang Formula (QQHCF) is a traditional Chinese medicine prescription that is clinically …
International clinical practice guideline on the use of traditional Chinese medicine for ulcerative colitis by Board of Specialty Committee of Digestive System Disease of World Federation of Chinese Medicine Societies (2023).
Zhang S, Zhao L, Shen H, Tang Z, Qin D, Li J, Zhang B, Yang G, Chen M, Wu K, Liu Z, Yang H, Wang H, Zong Y, Chen Y, Xiao S, Cai Q. Zhang S, et al. Among authors: shen h. Phytother Res. 2024 Feb;38(2):970-999. doi: 10.1002/ptr.8087. Epub 2023 Dec 19. Phytother Res. 2024. PMID: 38112572 Review.
Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.
Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, Yu Y, Yao W, Sun S, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Hu C, Liu J, Liu Y, Wang M, Li X, Sun P, Shu Y, Zhou J, Li J, Gu K, Wang C, Zhao H, Zhang Y, Liu C, Wang J, Chen R, Qin M, Wang H, Yang J. Zhou C, et al. Among authors: shen h. Nat Cancer. 2024 Jan;5(1):209. doi: 10.1038/s43018-023-00719-4. Nat Cancer. 2024. PMID: 38182915 No abstract available.
41 results